Renaissance Capital logo

PPD Priced, Nasdaq: PPD

LBO'd contract research organization that provides drug development services.

Industry: Health Care

First Day Return: +11.1%

Industry: Health Care

We are a leading provider of drug development services to the biopharmaceutical industry, focused on helping our customers bring their new medicines to patients around the world. We have been in the drug development services business for more than 30 years, providing a comprehensive suite of clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations, as well as other industry participants. Over that time, we have developed a track record of consistent quality, delivery and continuous innovation that has enabled us to grow faster than our underlying market over the past five years and deliver strong financial results. In 2018, we served all of the top 50 biopharmaceutical companies in the world, as ranked by 2018 research and development spending, and were involved in 66 drug approvals. We also participated in the development of all of 2018's top ten selling drugs, as ranked by 2018 revenue. Since 2014, we have also worked with over 300 companies in the growing biotechnology sector through our PPD Biotech model, which was built specifically to serve the unique needs of this customer segment.
more less
IPO Data
IPO File Date 01/09/2020
Offer Price $27.00
Price Range $24.00 - $27.00
Offer Shares (mm) 60.0
Deal Size ($mm) $1,620
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/05/2020
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $1,620
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Wilmington, NC, United States
Founded 1985
Employees at IPO 23,000
Website www.ppdi.com

PPD (PPD) Performance